Clinical Trial Update: Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating low-dose daunorubicin in pediatric relapsed/refractory acute leukemia has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia

Drugs mentioned

• Daunorubicin (daunorubicin)

Snippet

Sponsor: Children's Mercy Hospital Kansas City | Conditions: Relapsed Pediatric ALL, Relapsed Pediatric AML | Phase 2 | Status: COMPLETED | Results posted: 2023-05-06